This trial is testing a new cancer drug, LM-108, to see if it is safe and effective. The trial will involve patients with advanced solid tumors.
- Advanced Solid Tumors
4 Primary · 12 Secondary · Reporting Duration: 126 weeks
Side Effects for
Awards & Highlights
4 Treatment Groups
LM-108 Dose Escalation
1 of 4
LM-108 Combination Dose Expansion
1 of 4
LM-108 Dose Expansion
1 of 4
LM-108 Combination Dose Escalation
1 of 4
54 Total Participants · 4 Treatment Groups
Primary Treatment: LM-108 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Why did patients apply to this trial?
- "I am doing what I can to be better, I can ache at times."
How many prior treatments have patients received?
Frequently Asked Questions
Is this trial enrolling participants at present?
"Affirmative. Clinicaltrials.gov shows that this study is actively inviting participants, having been posted on May 26th 2022 and most recently edited on the 29th of the same month. This trial requires 54 test subjects to be recruited from 6 different sites." - Anonymous Online Contributor
How many facilities are actively administering this experiment?
"This clinical trial is recruiting from 6 different locations; three of which are Cincinnati, Dallas and Indianapolis. To minimize the amount of travel required to partake in this study, it may be wise to select a site closest to you." - Anonymous Online Contributor
How many applicants are being accepted for inclusion in this experiment?
"54 qualified patients are necessary for the successful completion of this research, which is being carried out by LaNova Medicines Limited across multiple sites such as The Christ Hospital in Cincinnati and Mary Crowley Cancer Research in Dallas." - Anonymous Online Contributor